Focal seizure

Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results

Retrieved on: 
Tuesday, March 5, 2024
Central nervous system, Quarter, EMA, Focal seizure, Research, New Drug Application, UCB, FDA, Partnership, Food, Part, Quantitative electroencephalography, SCN8A, Tremor, SCN2A, Safety, PPR, European Medicines Agency, CNS, EEG, Pharmacokinetics, Part 1, Patient, Essential tremor, Medicine, Epilepsy, DEE, Trial of the century, NDA, Ageing, Central nervous system disease, Seizure, Pharmaceutical industry

Fourth Quarter and Full Year 2023 Financial Results:

Key Points: 
  • Fourth Quarter and Full Year 2023 Financial Results:
    As of December 31, 2023, Praxis had $81.3 million in cash and cash equivalents, compared to $100.5 million in cash, cash equivalents and marketable securities as of December 31, 2022.
  • Research and development expenses were $18.4 million for the fourth quarter of 2023, compared to $28.3 million for the fourth quarter of 2022.
  • General and administrative expenses were $9.9 million for the fourth quarter of 2023, compared to $13.1 million for the fourth quarter of 2022.
  • Praxis incurred a net loss of $26.9 million for the fourth quarter of 2023, including $5.7 million of stock-based compensation expense, compared to $41.2 million for the fourth quarter of 2022, including $6.4 million of stock-based compensation expense.

Focal Epilepsy Often Overlooked

Retrieved on: 
Tuesday, October 20, 2020
Seizure types, Health, Epilepsy, Clinical medicine, Neurology, Focal seizure, Medicine, Epilepsy Phenome/Genome Project, Epilepsy syndromes

The study, publishing online Oct. 20 in the journal Epilepsia, addressed focal epilepsy, the most common form of this brain disorder.

Key Points: 
  • The study, publishing online Oct. 20 in the journal Epilepsia, addressed focal epilepsy, the most common form of this brain disorder.
  • "Our study highlights how common the early and subtle signs of focal epilepsy are," says study senior investigator Jaqueline A. French, MD, a professor of neurology and director of translational research and clinical trials for epilepsy at NYU Langone Health.
  • The World Health Organization estimates that at least 50 million people worldwide have epilepsy, including the most common focal epilepsy, affecting one in 26 American adults.
  • Researchers believe the impact of earlier diagnosis in focal epilepsy patients goes beyond more timely treatment of patients.

FDA approves first generic version of Sabril to help treat seizures in adults and pediatric patients with epilepsy

Retrieved on: 
Wednesday, January 16, 2019
Health, Seizure types, RTT, Pharmaceutical industry, Medicine, Epileptic seizure, Focal seizure, Generic drug, Food and Drug Administration

"We know there has been past interest in developing a generic alternative to this product.

Key Points: 
  • "We know there has been past interest in developing a generic alternative to this product.
  • We're especially focused on new policies aimed at making the generic review process more predictable, efficient and lower cost so we can entice more generic firms to enter this space, and help facilitate more generic drug launches after generic approvals.
  • Complex partial seizures, a common type of seizures, start in a specific area of the brain and can affect consciousness.
  • The FDA has continued to emphasize that even in the case of limited distribution programs, there should be a path forward for generic drug development.